Topical microbicides for the prevention of sexually transmitted diseases and HIV

Canadian Journal of Infectious Diseases

Volumn 10, Issue SUPPL. 3, 1999, Pages

  Désormeaux, André ^a   Omar, Rabeea F ^a   Bergeron, Michel G ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Human immunodeficiency virus; Prevention; Sexually transmitted diseases; Topical microbicides

Indexed keywords

EID: 0002293026     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/1999/932936     Document Type: Article

References (61)

1. Ebrahim SH, Peterman TA, Zaidi AA, Kamb ML. Mortality related to sexually transmitted diseases in US women, 1973 through 1992. Am J Public Health 1997;87:938-44.
2. Irwin K, Scarlett M, Moseley R. Observations from the CDC. The urgent need for new HIV/STD prevention options for women. J Women's Health 1998;7:1081-6.
3. Crotchfelt KA, Welsh LE, DeBonville D, Rosenstraus M, Quinn TC. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in genitourinary specimens from men and women by a coamplification PCR assay. J Clin Microbiol 1997;35:1536-40.
4. Fox J. Reports on worldwide HIV paint ever-grimmed picture. ASM News 1998;64:73-4.
5. The Centers for Disease Control and Prevention. Trends in sexual risks behaviors among high school students - United States, 1991-1997. Morb Moral Wkly Rep 1998;47:749-52.
6. Brugha R, Keersmaekers K, Renton A, Meheus A. Genital herpes infection: a review. Int J Epidemiol 1997;26:698-709.
7. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
8. Fox J. Researchers seek ways to curb mother-to-child HIV transmission. ASM News 1997;63:594-5.
9. Datta P, Embree JE, Kreiss JK, et al. Mother-to-child transmission of human immunodeficiency virus type 1: report from the Nairobi study. J Infect Dis 1994;170:1134-40.
10. Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997;336:1072-8.
11. Miller JM, McGhee JR, Gardner MB. Mucosal immunity, HIV transmission, and AIDS. Lab Invest 1992;68:130-45.
12. Masurier C, Salomon B, Guettari N, et al. Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice. J Virol 1998;72:7822-9.
13. Fox CH, Hoover S, Curral VR, Bahre HJ, Cottler-Fox M. HIV in infected lymph nodes. Nature 1994;370:256.
14. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
15. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62.
16. Tacchetti C, Favre A, Moresco L, et al. HIV is trapped and masked in the cytoplasm of lymph node follicular dendritic cells. Am J Pathol 1997;150:533-42.
17. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011-8.
18. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95-102.
19. De Wit JBF, Van Griensven GJP, Kok G, Sandfort TGM. Why do homosexual men relapse into unsafe sex? Predictors of resumption of unprotected anogenital intercourse with casual partners. AIDS 1993;7:1113-8.
20. McCusker J, Stoddard AM, McDonald M, Zapka JG, Mayer KH. Maintenance of behavioral change in a cohort of homosexually active men. AIDS 1992;6:861-8.
21. Elias CJ, Heise LL. Challenges for the development of female-controlled vaginal microbicides. AIDS 1994;8:1-9.
22. Feldblum PJ, Morrison CS, Roddy RE, Cates W Jr. The effectiveness of barrier methods of contraception in preventing the spread of HIV. AIDS 1995;9(Suppl A):S85-93.
23. Claypool LE, Krause P. Development of vaginal microbicides by the CONRAD program: A collaborative effort for research and product development. The 11th International Conference on AIDS. Vancouver, July 7 to 12, 1996.
24. Elias C. Female-controlled methods to prevent sexual transmission of HIV. The 11th International Conference on AIDS. Vancouver, July 7 to 12, 1996.
25. Short RV. Contraceptives of the future in the light of HIV infection. Aust NZ J Obstet Gynaecol 1994;34:330-2.
26. Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health 1990;80:460-2.
27. Rosenthal SL, Cohen SS, Stanberry LR. Topical microbicides. Current status and research considerations for adolescent girls. Sex Transm Dis 1998;25:368-77.
28. Niruthisard S, Roddy RE, Chutivongse S. The effect of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis 1991;18:176-9.
29. Roddy RE, Cordero M, Cordero C, Fortney JA. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS 1993;4:165-70.
30. Stafford MK, Ward H, Flanagan A, et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:327-31.
31. Van Damme L, Niruthisard S, Atisook R, et al. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS 1998;12:433-7.
32. Martin HL Jr, Stevens CE, Richardson BA, et al. Safety of a nonoxynol-9 vaginal gel in Kenyan prostitutes. Sex Transm Dis 1997;24:279-83.
33. Goeman J, Ndoye I, Sakho LM, et al. Frequent use of menfegol spermicidal vaginal foaming tablets associated with a high incidence of genital lesions. J Infect Dis 1995;171:1611-4.
34. Klebanoff SJ. Effects of the spermicidal agent nonoxynol-9 on vaginal microbial flora. J Infect Dis 1992;165:19-25.
35. McGroarty JA, Chung S, Reid G, Bruce AW. Influence of the spermicidal compound nonoxynol-9 on the growth and adhesion of urogenital bacteria in vitro. Curr Microbiol 1990;21:219-23.
36. McGroarty JA, Tomeczek L, Pond DG, Reid G, Bruce AW. Hydrogen peroxide production by Lactobacillus species: correlation with susceptibility to the spermicidal compound nonoxynol-9. J Infect Dis 1992;165:1142-4.
37. Reid G, McGroarty JA, Tomeczek L, Bruce AW. Identification and plasmid profiles of Lactobacillus species from the vagina of 100 healthy women. FEMS Immunol Med Microbiol 1996;15:23-6.
38. Richardson BA, Martin HLJ, Stevens CE, et al. Use of nonoxynol-9 and changes in vaginal lactobacilli. J Infect Dis 1998;178:441-5.
39. Rosenstein IJ, Stafford MK, Kitchen VS, Ward H, Weber JN, Taylor-Robinson D. Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1. J Infect Dis 1998;177:1386-90.
40. Chermann JC, Barré-Sinoussi F, Hénin Y, Maréchal V. HIV inactivation by a spermicide containing benzalkomium chloride. AIDS Forsch 1987;2:85-6.
41. Hicks DR, Martin LS, Gethell JP, et al. Inactivation of HTLV-III-LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro. Lancet 1985;ii:1422-3.
42. Judson FN, Ehret JM, Bodin GF, Levin MJ, Rietmeijer CAM. In vitro evaluations of condoms with and without nonoxynol-9 as physical and chemical barriers against Chlamydia trachomatis, herpes simplex virus type 2, and human immunodeficiency virus. Sex Transm Dis 1989;16:51-6.
43. Singh B, Posti B, Cutler JC. Virucidal effect of certain chemical contraceptives in type 2 herpesvirus. Am J Obstet Gynecol 1976;126:422-5.
44. Wainberg MA, Bleau G. Effects of benzalkonium chloride on the human immunodeficiency virus (HIV-1) and other infectious agents. Arch AIDS Res 1987;1:57-67.
45. Wainberg MA, Spira B, Bleau G, Thomas R. Inactivation of human immunodeficiency virus type 1 in tissue culture fluid and in genital secretions by the spermicide benzalkonium chloride. J Clin Microbiol 1990;28:156-8.
46. Benes S, McCormack WM. Inhibition of growth of Chlamydia trachomatis by nonoxynol-9 in vitro. Antimicrob Agents Chemother 1985;27:724-6.
47. Kelly JP, Reynolds RB, Stagno S, Louv WC, Alexander WJ. In vitro activity of the spermicide nonoxynol-9 against Chlamydia trachomatis. Antimicrob Agents Chemother 1985;27:760-2.
48. Jennings R, Clegg A. The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in vitro. J Antimicrob Chemother 1993;32:71-82.
49. Malkovsky M, Newell A, Dalgleish AG. Inactivation of HIV by nonoxynol-9. Lancet 1988;i:645.
50. Zekeng L, Feldblum PJ, Oliver RM, Kaptue L. Barrier contraceptive use and HIV infection among high-risk women in Cameroon. AIDS 1993;7:725-31.
51. Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992;268:477-82.
52. Hira SK, Feldblum PJ, Kamanga J, Mukelabai G, Weir SS, Thomas JC. Condom and nonoxynol-9 use and the incidence of HIV infection in serodiscordant couples in Zambia. Int J STD AIDS 1997;8:243-50.
53. Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL. A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998;339:504-10.
54. McClure DA, Edelman DA. Worldwide method effectiveness of the Today® vaginal contraceptive sponge. Adv Contracept 1985;1:305-11.
55. Larkin M. Easing the way to safer sex. Lancet 1998;351:964.
56. Mayer K, Peipert J, Fleming T, et al. BufferGel: Results of the first phase I study of a novel vaginal microbicide. 12th World AIDS Conference. Geneva, June 28 to July 3, 1998.
57. Rusconi S, Moonis M, Merrill DP, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996;40:234-6.
58. Wright A, Rosenstein I, Poulter L, et al. Safety and tolerability of PRO 2000 gel: A potential vaginal virucide. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, January 31 to February 4, 1998.
59. Profy AT, Sonderfan AJ, Bourne N, et al. PRO 2000 gel, a potential topical microbicide for HIV prevention, can block infection by other sexually transmitted disease pathogens. 12th World AIDS Conference. Geneva, June 28 to July 3, 1998.
60. Gagné N, Cormier H, Omar RF, et al. Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9. Sex Transm Dis 1999;26:177-83.
61. Bergeron MG, Gagné N, Désormeaux A, et al. Efficacy of a gel formulation to prevent the transmission of pathogens causing sexually transmitted diseases. 12th World AIDS Conference. Geneva, June 28 to July 3, 1998.